Feng Cong is the Director and the Cambridge Pathways Hub Leader for the Developmental and Molecular Pathways department. Feng’s group has focused on therapeutics targeting developmental pathways, especially the Wnt signaling pathway, in cancer and degenerative diseases. His team has utilized chemical, genetic, and proteomics approaches and performed in-depth pathway dissection. Their work led to discovery of two therapeutically-relevant mechanisms regulating Wnt signaling, including control of Axin stability by Tankyrase and control of Frizzled turnover by the R-spondin receptor system. Feng and his colleagues have built a portfolio of small molecule and antibody projects, with some advancing to the late discovery stages. He has been recognized as a Novartis Leading Scientist.

Feng Cong received his PhD in 2000 from Columbia University, where he worked in the laboratory of Stephen P. Goff. He completed a postdoctoral fellowship in 2004 at Memorial Sloan Kettering Cancer Center, under the supervision of Harold E. Varmus.